Tag: signals

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

James Altucher: Starlink Authorized to Deploy Thousands More Satellites.

James Altucher walks through what Starlink's expanding constellation signals about the company's future and why most investors haven't connected the dots.

James Altucher walks through what Starlink's expanding constellation signals about the company's future and why most investors haven't connected the dots.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsSignals

easyGroup enters online retail with launch of easyShop.com marketplace in partnership with OnBuy.com

Viral Sunglasses Brands in 2026: Why Quay Is Becoming a Go-To Choice for Trend-Driven Shoppers According to Consumer365

New Report Reveals 3 in 4 CRNAs Got a Raise Last Year While Most Remain Just One Good Offer Away from a Career Move

Tag: signals

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

James Altucher: Starlink Authorized to Deploy Thousands More Satellites.

Tredence Named 2026 Retail & Consumer Goods Snowflake Services Partner of the Year 2026, for the Second Consecutive Year

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Toyota’s Collaborative Safety Research Center Touts Partnerships, Eyes Future with Announcement of 10 New Projects

GetYourGuide unveils summer 2026’s three defining travel trends

Camp Safety, Preparedness, and Protecting America’s Youth

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Cyware Expands Threat Intelligence Suite with new Digital Risk Protection

Afreximbank Deepens Commitment to Economic Progress in The Bahamas

Action1 Lands at Infosecurity Europe as Autonomous Patching Becomes the New Compliance Standard

ICIS expands polymer demand insight to help customers make better decisions across global plastics markets

ICIS expands polymer demand insight to help customers make better decisions across global plastics markets

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us